Video

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

Author(s):

Charu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Related Videos
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Steven H. Lin, MD, PhD
Related Content
OncLive's Top Stories of the Week
November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Lung Cancer - stock.adobe.com
November 26th 2024

Tiragolumab Plus Atezolizumab Fails to Meet OS End Point in PD-L1–High NSCLC

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Zorifertinib for EGFR+ NSCLC With CNS Metastases | Image Credit: © Cornflakesei - stock.adobe.com
November 20th 2024

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

Lung Cancer
November 19th 2024

Subcutaneous Pembrolizumab Plus Chemo Meets Pharmacokinetic End Points in NSCLC